Literature DB >> 9564447

Antipanic effect of fluoxetine measured by CO2 challenge test.

V Bocola1, M D Trecco, G Fabbrini, C Paladini, A Sollecito, N Martucci.   

Abstract

BACKGROUND: Respiratory symptoms are important in panic disorder for frequency and intensity. Patients with this disorder are often chronic hyperventilators, and inhalation of carbon dioxide is a strong panicogenic stimulus. We tested the hypothesis of whether respiratory parameters may be used as indicators of the course of panic disorder during its treatment with fluoxetine.
METHODS: Nine patients with panic disorders, previously shown to panic in response to intravenously administered lactate, and 10 control subjects underwent the Read rebreathing test by a 5-min inhalation of a 7% CO2/93% O2 mixture before and after 1 month of fluoxetine treatment.
RESULTS: At baseline, patients differed from controls for higher percent value of expiratory reserve volume/vital capacity ratio and ventilatory response. Eight of the 9 patients had panic in response to the CO2 challenge. After fluoxetine, respiratory parameters decreased significatively, and only 3 patients remained hypercarbic challenge responders.
CONCLUSIONS: The carbon dioxide challenge may represent a useful tool to evaluate the individual respiratory set, which may be a marker of the vulnerability to panic attack. Assessment of respiratory parameters may represent a biological marker to measure the efficacy of antipanic treatment.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9564447     DOI: 10.1016/s0006-3223(97)00221-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  2 in total

1.  Chronic serotonin-norepinephrine reuptake transporter inhibition modifies basal respiratory output in adult mouse in vitro and in vivo.

Authors:  Kelly A Warren; Irene C Solomon
Journal:  Respir Physiol Neurobiol       Date:  2012-07-31       Impact factor: 1.931

2.  The influence of opioids and nonopioid central nervous system active medications on central sleep apnea: a case-control study.

Authors:  Ronald Gavidia; Amara Emenike; Anran Meng; Erica C Jansen; Shelley Hershner; Cathy Goldstein; Judy Fetterolf; Galit Levi Dunietz
Journal:  J Clin Sleep Med       Date:  2021-01-01       Impact factor: 4.062

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.